Showing results (21-30 of 343) with videos related to
Sort By:
Pageof 35
European Journal of Heart Failure|August 18, 2012
Heart failure highlights in 2011B Daan Westenbrink, Kevin Damman, Michiel Rienstra, et al.European Journal of Heart Failure|October 20, 2018
Treating oxidative stress in heart failure: past, present and futureAtze van der Pol, Wiek H van Gilst, Adriaan A Voors, et al.Expert Opinion on Investigational Drugs|November 21, 2015
Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failureLicette Cy Liu, Bernard Dorhout, Peter van der Meer, et al.European Journal of Heart Failure|January 28, 2014
Sex differences in cardiomyopathiesSven Meyer, Peter van der Meer, J Peter van Tintelen, et al.European Journal of Heart Failure|July 20, 2019
Cancer and heart disease: associations and relationsRudolf A de Boer, Wouter C Meijers, Peter van der Meer, et al.The Canadian Journal of Cardiology|February 26, 2014
A novel approach to drug development in heart failure: towards personalized medicineLicette C Y Liu, Adriaan A Voors, Mattia A E Valente, et al.Handbook of Experimental Pharmacology|April 7, 2017
Comorbidities in Heart FailureHaye H van der Wal, Vincent M van Deursen, Peter van der Meer, et al.Expert Opinion on Investigational Drugs|June 23, 2015
Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney diseaseLicette C Y Liu, Elise Schutte, Ron T Gansevoort, et al.Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|March 6, 2025
Identification of disease-specific pathways and modifiers in phospholamban R14del cardiomyopathy: rationale, design and baseline characteristics of DECIPHER-PLN cohortFrederik E Deiman, Remco de Brouwer, Lukas Baumhove, et al.European Heart Journal|February 27, 2004
Erythropoietin in cardiovascular diseasesPeter van der Meer, Adriaan A Voors, Erik Lipsic, et al.Pageof 35